Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2015 Jun;56(6):1665-70.
doi: 10.3109/10428194.2014.963078. Epub 2014 Oct 30.

Survival in patients with limited-stage peripheral T-cell lymphomas

Robert Briski  1 , Andrew L Feldman, Nathaniel G Bailey, Megan S Lim, Kay Ristow, Thomas M Habermann, William R Macon, David J Inwards, Joseph P Colgan, Grzegorz S Nowakowski, Mark S Kaminski, Thomas E Witzig, Stephen M Ansell, Ryan A Wilcox
Affiliations
Multicenter Study

Survival in patients with limited-stage peripheral T-cell lymphomas

Robert Briski et al. Leuk Lymphoma. 2015 Jun.

Abstract

The natural history of limited-stage peripheral T-cell lymphoma (PTCL) remains poorly defined. Therefore, we examined outcomes in patients with the most common PTCL subtypes (PTCL, not otherwise specified [PTCL, NOS], angioimmunoblastic T-cell lymphoma [AITL], anaplastic large cell lymphoma [ALCL]) and limited-stage disease. In this retrospective, multicenter study, 75 patients with limited-stage disease were identified. The median event-free survival (EFS) and overall survival (OS) observed were 2.1 and 6.5 years, respectively. In a landmark analysis excluding patients with primary refractory disease, no significant benefit was observed for patients undergoing consolidative radiation therapy. With the exception of patients undergoing salvage hematopoietic stem cell transplant, survival following disease relapse or progression was poor, thus highlighting the need for improved therapeutic strategies.

Keywords: Peripheral T-cell lymphoma; prognosis; radiation.

PubMed Disclaimer

Conflict of interest statement

CONFLICT-OF-INTEREST AND DISCLOSURE

The authors declare no competing financial interests.

Figures

Figure 1
Figure 1
Event-free (a) and overall (b) survival in limited stage PTCL (PTCL-NOS, AITL, and ALCL).
Figure 2
Figure 2
Event-free (a, c) and overall (b, d) survival of limited stage PTCL (PTCL-NOS, AITL, ALCL) patients who received front-line combination chemotherapy with (—) or without (·····) radiotherapy. A landmark analysis, including those who achieved a complete or partial remission following front-line combination chemotherapy, is shown (c, d).
Figure 3
Figure 3
Event-free (a) and overall (b) survival of limited and advanced staged PTCL (PTCL-NOS, AITL, ALCL) patients following first relapse or progression. Event-free (c) and overall (d) survival following first relapse or progression stratified by initial stage.
See this image and copyright information in PMC

References

    1. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–4130. - PubMed
    1. Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, Rudiger T, Pileri S, Nakamura S, Nathwani B, Campo E, Berger F, Coiffier B, Kim WS, Holte H, Federico M, Au WY, Tobinai K, Armitage JO, Vose JM. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117:3402–3408. - PubMed
    1. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15:1467–1475. - PubMed
    1. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, Zaja F, Cortelazzo S, Rigacci L, Devizzi L, Todeschini G, Santini G, Brugiatelli M, Federico M Intergruppo Italiano L. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474–2479. - PubMed
    1. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339:21–26. - PubMed

Publication types

LinkOut - more resources